Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas (FollowTheDIN)

A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With Investigator's Choice of Chemotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas With High Levels of GD2 Expression and Disease Progression During 1st Line Chemotherapy

Data from 40 patients are planned to be included in the study to randomize approximately 10 patients.

This study involves patients with advanced/metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy, advanced/metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy and advanced/metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy.

All patients will receive therapy until disease progression (a total of 6 courses of immunotherapy).

The primary objective of the study is to determine the efficacy and safety of dinutuximab beta with investigator's choice of chemotherapy.

Study Overview

• Status: Recruiting
• Conditions: Alveolar Rhabdomyosarcoma; Embryonal Rhabdomyosarcoma; Bone Sarcoma
• Intervention / Treatment: Drug: dinutuximab beta

Detailed Description

Data from 40 patients are planned to be included in the study to randomize approximately 10 patients.

This study involves patients with advanced/metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy, advanced/metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy and advanced/metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy.

6 cycles of treatment with dinutuximab beta are provided in combination with 6-8 cycles of chemotherapy during the induction therapy phase. Switching from one chemotherapy regimen to another is not allowed. Dinutuximab beta should be administered as a slow intravenous infusion through a separate catheter using an infusion pump.

All patients will receive therapy until disease progression (a total of 6 courses of immunotherapy).

Treatment response will be assessed by the investigator after 2, 4 cycles of treatment and at the end of the reinduction therapy period (i.e., after 6 cycles of dinutuximab beta treatment and 6 - 8 cycles of polychemotherapy). Treatment response will be assessed by tumor response according to the criteria for response assessment in the treatment of solid tumors (RECIST 1.1).

After discontinuation of therapy, all patients will be followed up for 6 months. All patients should be followed up to assess survival unless consent is withdrawn. Long-term follow-up/survival assessment visits will be performed monthly until death, withdrawal of consent, or study termination, whichever occurs first.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 3

Contacts and Locations

• Study Contact: Name: Svetlana Kulyova, MD, Phd; Phone Number: +79213357588 +78124399555; Email: Kulevadoc@yandex.ru

Study Locations

• Russian Federation
  • St. Petersburg, Russian Federation, 194362
    • Recruiting
    • Kulyova Svetlana
    • Contact: Svetlana Kulyova, MD, PhD; Phone Number: +781243995553301; Email: Kulevadoc@yandex.ru
    • Contact: Svetlana Kulyova, MD, PhD; Phone Number: +79213357588; Email: Kulevadoc@yandex.ru

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Signed written informed consent form;
2. Age under 18 years of age;
3. Histologically confirmed GD2-positive osteogenic sarcoma, Ewing's sarcoma, soft tissue and undifferentiated sarcomas;
4. Prior to study enrollment, patients must have been treated with one or more lines of adequate chemotherapy and must have relapsed on this therapy or have refractoriness to it;
5. General satisfactory condition of the patient (Lansky scale activity 80-100% (children under 16 years of age), Karnofsky scale 80-100% (children over 16 years of age); ECOG - 0-1);
6. Sufficient cardiopulmonary reserves of the patient's organism (ECG (ELECTROCARDIOGRAPHY) data within normal limits, ventricular ejection fraction > 75% of the upper limit of normal;

7. Adequate liver function (ALT (ALANINE AMINOTRANSFERASE) ≤ 2.5 * VGN, AST (ASPARTATE AMINOTRANSFERASE) ≤ 2.5 * VGN), kidney (creatinine <1.5 * VGN), red bone marrow (granulocytes> 2.0 * 109/L, platelets> 150 * 109/L).

   Six months later, two additional criteria were formulated:

8. Life expectancy at the time of initiation of therapy within the framework of the study is not less than 12 months
9. Oligometastasis disease (presence of 1 to 5 distant metastatic foci) at restaging at the time of the decision to include the patient in the study;

Exclusion Criteria:

1. Withdrawal of consent by the patient or his/her parent/guardian.
2. Exclusion of the patient by the investigator for safety or ethical reasons.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Generalized / metastatic GD2-positive rhabdomyosarcoma; Generalized / metastatic GD2-positive rhabdomyosarcoma after progression on 1st line of chemotherapy. Chemotherapy options: • CARBO(CARBOPLATIN) + ETO(ETOPOSIDE), IFO(IFOSFAMIDE) + ETO(ETOPOSIDE), CARBO(CARBOPLATIN) + IFO(IFOSFAMIDE) (rhabdomyosarcoma) + 6 consecutive cycles of dinutuximab beta immunotherapy	Drug: dinutuximab beta; Chemotherapy + Immunotherapy (dinutuximab beta)
Experimental: Generalized / metastatic GD2-positive Ewing sarcoma; Generalized / metastatic GD2-positive Ewing sarcoma after progression on 1st line of chemotherapy. • ICE (IFOSFAMIDE+CARBOPLATIN+ETOPOSIDE), TEM(TEMOZOLOMIDE+IRINOTECAN), VCT(VINCRISTINE+CYCLOPHOSPHAN+TOPOTECAN), TC(CYCLOPHOSPHAN+TOPOTECAN), TT(TEMOZOLOMIDE+TOPOTECAN), GEM/TAX(GEMCITABINE+DOCETAXEL) (Ewing's sarcoma) + 6 consecutive cycles of dinutuximab beta immunotherapy	Drug: dinutuximab beta; Chemotherapy + Immunotherapy (dinutuximab beta)
Experimental: Generalized / metastatic GD2-positive osteosarcoma; Generalized / metastatic GD2-positive osteosarcoma after progression on 1st line of chemotherapy. • ICE(IFOSFAMIDE+CARBOPLATIN+ETOPOSIDE), IE (IFOSFAMIDE+ETOPOSIDE), CARBOPLATIN+ ETOPOSIDE, Аi(DOXORUBICIN+IFOSFAMIDE), IFO(IFOSFAMIDE), GEM/TAX(GEMCITABINE+DOCETAXEL) (osteosarcoma) + 6 consecutive cycles of dinutuximab beta immunotherapy	Drug: dinutuximab beta; Chemotherapy + Immunotherapy (dinutuximab beta)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progression-free survival (PFS)	PFS will be assessed from the date of the first induction dose of dinutuximab beta to the date of first documented disease progression or death from any cause.	6 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival (OS)	OS will be assessed from the date of administration of the first induction dose of dinutuximab beta to the date of death.	6 months
Overall response rate (ORR)	ORR will be assessed by tumor response CR or PR.	6 months
Tumor control rate (TCR)	TCR will be assessed by tumor response according CR + PR + stabilization.	6 months
Duration of response (DR)	DR will be assessed from initial response to disease progression.	6 months
Immune-associated adverse events (IAAE)	IAAE will be assessed from the date of administration of the first induction dose of dinutuximab beta to the date of death.	6 months

Collaborators and Investigators

• Sponsor: N.N. Petrov National Medical Research Center of Oncology
• Investigators: Principal Investigator: Svetlana Kulyova, MD, Phd, Head of Children's Oncology Department

Study record dates

Study Major Dates

• Study Start (Actual): May 20, 2021
• Primary Completion (Estimated): September 1, 2025
• Study Completion (Estimated): September 1, 2025

Study Registration Dates

• First Submitted: October 30, 2024
• First Submitted That Met QC Criteria: October 31, 2024
• First Posted (Estimated): November 1, 2024

Study Record Updates

• Last Update Posted (Estimated): November 1, 2024
• Last Update Submitted That Met QC Criteria: October 31, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms; Neoplasms by Histologic Type; Neoplasms, Connective and Soft Tissue; Neoplasms, Muscle Tissue; Myosarcoma; Sarcoma; Rhabdomyosarcoma; Rhabdomyosarcoma, Embryonal; Rhabdomyosarcoma, Alveolar; Antineoplastic Agents; Dinutuximab
• Other Study ID Numbers: 821052021

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No